Oscar Health, Inc. (OSCR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.2% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Oscar Health, Inc. (OSCR) Advances While Market Declines: Some Information for Investors
- Why Oscar Health (OSCR) Is Up 8.6% After Raising 2026 Outlook On AI-Driven Q2 Beat
- Oscar Health Trading at a Premium: Why Should You Still Buy It?
- Oscar Health, Inc. (OSCR) Stock Dips While Market Gains: Key Facts
- All You Need to Know About Oscar Health (OSCR) Rating Upgrade to Strong Buy
- Best Momentum Stocks to Buy for September 23rd
- Oscar Health, Inc. (OSCR) Stock Drops Despite Market Gains: Important Facts to Note
- Zacks Industry Outlook Prudential Financial, Assurant, Oscar and Horace Mann
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Oscar Health, Inc..
Full OSCR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.